简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

CD & R、TPG以40亿美元收购Covetrus私有化

2022-05-25 21:48

  • Clayton, Dubilier & Rice (CD&R), a private investment firm, and TPG Capital will acquire animal-health technology and services company Covetrus Inc (NASDAQ:CVET) for $21.00 per share, representing an enterprise value of approximately $4 billion.
  • CD&R and its affiliates currently beneficially own approximately 24% of the company's outstanding shares of common stock. 
  • The transaction represents a 39% premium to Covetrus' 30-day volume-weighted average price per share as of the unaffected stock price as of May 13, 2022.
  • Related: Raymond James View Skewed Scenarios On Absent Supportive Bid For This Animal Health Stock.
  • "Covetrus has undergone a true transformation since our initial 2015 investment in its predecessor, Vets First Choice, growing from $55 million in revenue focused primarily on online pharmacy in the US to a leading global provider of animal health services with more than $4.6 billion in revenue," said Sarah Kim, Partner at CD&R. 
  • The transaction is expected to close in the second half of 2022. 
  • Upon completing the transaction, Covetrus will become a private company and no longer be publicly listed or traded on NASDAQ. 
  • Covetrus' management team, including Benjamin Wolin, President & CEO, is expected to continue to lead the company. 
  • Covetrus plans to maintain its headquarters in Portland, Maine, and will continue to operate under its current brands.
  • Price Action: CVET shares are up 4.20% at $20.49 during the market session on the last check Wednesday.

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。